HMGB1 and neoplasm: During ICD, tumor cells release damage‐associated molecular patterns (DAMPs), such as calreticulin (CRT), adenosine triphosphate (ATP), and high mobility group box 1 protein (HMGB1), that promote immune system activation (Figure 1a), effectively transforming dying tumor cells into a source of in situ immunization.[1, 2] In recent years, metal complexes have emerged as potent and versatile ICD inducers, capable of engaging diverse cellular stress pathways while offering chemical modularity and tunable pharmacology.[3, 4]